While there are limitations in the use of a single-marker (CD68) for lesion staging, we thought it important to implement the consensus lesion staging criteria for histological classification of MS lesions using myeloid markers for comparability across pathological studies. The gene discussed is CD68; the disease is myeloid sarcoma.